Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $17.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Munshi NC and Anderson KC (2005) To transplant or not to transplant? Blood 106: 3687–3688
Singhal S et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565–1571
Richardson P et al. (2004) Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 79: 875–882
Richardson PG et al. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063–3067
Rajkumar SV et al. (2006) Phase III clinical trial of thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24: 431–436
Attal M et al. ((2006) Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood Jul 27 [Epub ahead of print]
Barlogie B et al. (2006) Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 107: 2633–2638
Palumbo A et al. (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367: 825–831
The synopsis was written by Alexandra King, Associate Editor, Nature Clinical Practice.
PG Richardson is on the Advisory Board and Speakers' Bureau for Celgene Corporation, and for Millennium Pharmaceuticals. CS Mitsiades is a consultant and receives honoraria from Millennium Pharmaceuticals, Novartis Pharmaceuticals, Bristol-Myers Squibb and Merck & Co. NC Munshi is on the Advisory Board and Speakers' Bureau for Celgene Corporation, Millennium Pharmaceuticals and Novartis Pharmaceuticals. KC Anderson is a consultant and receives honoraria and research support from Celgene Corporation, Millennium Pharmaceuticals and Novartis Pharmaceuticals.
About this article
The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma
Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: A pilot study
Annals of Oncology (2008)